These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1041 related items for PubMed ID: 25409858

  • 1. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B, Bennett K, Silke C, Whelan B.
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [Abstract] [Full Text] [Related]

  • 2. Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.
    Schulz M, Coleshill MJ, Day RO, Wright DFB, Brett J, Briggs NE, Aung E.
    Br J Clin Pharmacol; 2024 May; 90(5):1322-1332. PubMed ID: 38382554
    [Abstract] [Full Text] [Related]

  • 3. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A, Kim Y, Kim GT, Ahn E, So MW, Lee SG.
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [Abstract] [Full Text] [Related]

  • 4. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [Abstract] [Full Text] [Related]

  • 5. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Mitri G, Wittbrodt ET, Turpin RS, Tidwell BA, Schulman KL.
    J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
    [Abstract] [Full Text] [Related]

  • 6. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar MAFJ.
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [Abstract] [Full Text] [Related]

  • 7. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA, Akhras KS, Shiozawa A.
    Arthritis Res Ther; 2015 May 12; 17(1):120. PubMed ID: 25963969
    [Abstract] [Full Text] [Related]

  • 9. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.
    Curr Med Res Opin; 2009 Jul 12; 25(7):1711-9. PubMed ID: 19485724
    [Abstract] [Full Text] [Related]

  • 10. Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.
    Coleshill MJ, Day RO, Tam K, Kouhkamari M, Caillet V, Aung E, Kannangara DRW, Cronin P, Rodgers A, Stocker SL.
    Br J Clin Pharmacol; 2022 Nov 12; 88(11):4894-4901. PubMed ID: 35675118
    [Abstract] [Full Text] [Related]

  • 11. Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study.
    Steelandt A, Hittinger A, Kanagaratnam L, Kazes I, Clavel P, Bolko L, Rieu P, Salmon JH.
    BMC Nephrol; 2024 Aug 20; 25(1):266. PubMed ID: 39164615
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.
    Barry A, Helget LN, Androsenko M, Wu H, Kramer B, Newcomb JA, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Merriman TR, O'Dell JR, Mikuls TR.
    Arthritis Rheumatol; 2024 Oct 20; 76(10):1552-1559. PubMed ID: 38925627
    [Abstract] [Full Text] [Related]

  • 13. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM, Pentony P, McGill NW.
    Int J Rheum Dis; 2017 Jul 20; 20(7):894-897. PubMed ID: 28205336
    [Abstract] [Full Text] [Related]

  • 14. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
    Scheepers LEJM, Burden AM, Arts ICW, Spaetgens B, Souverein P, de Vries F, Boonen A.
    Rheumatology (Oxford); 2018 Sep 01; 57(9):1641-1650. PubMed ID: 29893941
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T, Pope JE.
    Rheumatology (Oxford); 2017 Jul 01; 56(7):1144-1153. PubMed ID: 28379501
    [Abstract] [Full Text] [Related]

  • 16. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC, Salido EO, Penserga EG.
    Mod Rheumatol; 2021 May 01; 31(3):755-761. PubMed ID: 32701037
    [Abstract] [Full Text] [Related]

  • 17. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, Mikuls TR.
    J Rheumatol; 2015 Mar 01; 42(3):504-12. PubMed ID: 25512479
    [Abstract] [Full Text] [Related]

  • 18. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Hill-McManus D, Marshall S, Soto E, Lane S, Hughes D.
    Value Health; 2018 Dec 01; 21(12):1373-1381. PubMed ID: 30502780
    [Abstract] [Full Text] [Related]

  • 19. Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
    So MW, Kim AR, Lee SG.
    Int J Rheum Dis; 2023 Sep 01; 26(9):1770-1778. PubMed ID: 37431263
    [Abstract] [Full Text] [Related]

  • 20. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Smolen LJ, Gahn JC, Mitri G, Shiozawa A.
    Clin Ther; 2016 Jul 01; 38(7):1710-25. PubMed ID: 27269247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.